α2A‐Adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice
Authors:
- 1 July 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (6) , 1287-1296
Abstract
Background and purpose: The imidazoline‐type α2‐adrenoceptor antagonists (±)‐efaroxan and phentolamine increase insulin secretion and reduce blood glucose levels. It is not known whether they act by antagonizing pancreatic β‐cell α2‐adrenoceptors or by α2‐adrenoceptor‐independent mechanisms. Many imidazolines inhibit the pancreatic β‐cell KATP channel, which is the molecular target of sulphonylurea drugs used in the treatment of type II diabetes. To investigate the mechanisms of action of (±)‐efaroxan and phentolamine, α2A‐adrenoceptor knockout (α2A‐KO) mice were used.Experimental approach: Effects of (±)‐efaroxan, 5 mg kg−1, and phentolamine, 1 mg kg−1, on blood glucose and insulin levels were compared with those of the non‐imidazoline α2‐adrenoceptor antagonist [8aR,12aS,13aS]‐5,8,8a,9,10,11,12,12a,13,13a‐decahydro‐3‐methoxy‐ 12‐(ethylsulphonyl)‐6H‐isoquino[2,1‐g][1,6]naphthyridine (RS79948‐197), 1 mg kg−1, and the sulphonylurea glibenclamide, in α2A‐KO and control (wild type (WT)) mice.Key results: In fed WT mice, (±)‐efaroxan, phentolamine and RS79948‐197 reduced blood glucose and increased insulin levels. Fasting abolished these effects. In fed α2A‐KO mice, (±)‐efaroxan, phentolamine and RS79948‐197 did not alter blood glucose or insulin levels, and in fasted α2A‐KO mice, blood glucose levels were increased. Glibenclamide, at a dose only moderately efficacious in WT mice (5 mg kg−1), caused severe hyperinsulinaemia and hypoglycaemia in α2A‐KO mice. This was mimicked in WT mice by co‐administration of RS79948‐197 with glibenclamide.Conclusions and implications: These results suggest that (±)‐efaroxan and phentolamine increase insulin secretion by inhibition of β‐cell α2A‐adrenoceptors, and demonstrate a critical role for α2A‐adrenoceptors in limiting sulphonylurea‐induced hyperinsulinaemia and hypoglycaemia.British Journal of Pharmacology (2008) 154, 1287–1296; doi:10.1038/bjp.2008.186; published online 19 May 2008Keywords
This publication has 66 references indexed in Scilit:
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- α2‐Adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of miceBritish Journal of Pharmacology, 2006
- The potential antidiabetic activity of some alpha-2 adrenoceptor antagonistsPharmacological Research, 2001
- Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretionBritish Journal of Pharmacology, 1997
- Normalization of insulin secretion by a selective alpha 2-adrenoceptor antagonist restores GLUT-4 glucose transporter expression in adipose tissue of type II diabetic ratsEndocrinology, 1996
- Studies of midaglizole (DG-5128). A new type of oral hypoglycemic drug in healthy subjectsDiabetes, 1987
- Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion.Journal of Clinical Investigation, 1983
- Important role of adrenergic mechanisms in acute glucose counterregulation following insulin-induced hypoglycemia in type I diabetes. Evidence for an effect mediated by beta-adrenoreceptorsDiabetes, 1982
- Role of Glucagon, Catecholamines, and Growth Hormone in Human Glucose CounterregulationJournal of Clinical Investigation, 1979
- Increase of Insulin Concentration in Maturity-Onset Diabetics by Phentolamine (Regitine®) InfusionHormone and Metabolic Research, 1973